Proteomics and Lipidomics Core

蛋白质组学和脂质组学核心(C.Varie，核心主任) 蛋白质组学和脂质组学核心由Calvin Variy博士领导，提供高质量的研究设计 支持、样品制备、质谱分析、数据收集和数据分析 组织和细胞。间充质细胞的组成成分与代谢的神经调节 自2017年以来，我们的服务重点是老鼠和人类组织中的蛋白质和脂肪图谱。 我们的目标仍然是：1)提供新的方法来扩展以前的蛋白质识别能力，2) 为蛋白质组学和脂类组学研究提供公正的分析工作流程，包括3)进一步开发 目标蛋白质(例如，MRMHR、SRM)和脂类定量(MSMSALL、MPIS)工作流程，以及4)提供 改进了数据解释和机制识别的统计和信息学方法。 在此Cobre的第一阶段，蛋白质组学和脂质组学核心始终支持基础、翻译和 临床研究项目和拨款申请。这些人包括由年轻调查员发起的科布雷 MaineHealth内外的项目、Cobre试点项目和其他NIH研究应用 研究所。第一阶段的重大成就是授予NIH S10共享仪器 GRANT支持新的高分辨率TripleToF质谱仪、液相色谱仪等 支援设备。MaineHealth提供了机构资金来翻新设施，这巩固了 现有设备和新设备的使用效率更高。这种支持提高了我们的能力、效率、 通过允许扩展的蛋白质组学和脂质组学工作流程和增加的用户访问来实现更高的灵活性，同时 提供新的机会，支持对内部和外部用户进行的研究和培训。同相 我，我们聘请了一位杰出的质谱学技术经理，卡洛斯·加特纳博士，他带来了 专业知识，包括质谱学仪器和先进的液相色谱仪。我们也 招募Yulica Santos-Ortega博士作为以质谱学为基础的心血管研究助理 蛋白质组学经验。新的第二阶段机会包括开发全人类选定的蛋白质组 使用将在新仪器上实施的在线数据存储库的反应监测协议 (Sciex QTRAP 6500+)。我们继续独一无二地定位为唯一的地区性设施，提供 这些服务用于科学研究以及支持学生、研究人员和工作人员的培训。在这个范围内 科布雷，这些资源将是促进初级调查员晋升的关键。这一核心将向前推进 我们对生热脂肪细胞系的特性及其在能量平衡中的作用的理解(项目1， M.Lynes)，提供了X/A细胞分泌组在减肥手术相关骨丢失中的作用的洞察力(项目 2、Z.Li)。这个核心也将很好地支持PI的进展和未来的探索方向 确定心脏代谢性疾病中可改变的危险因素(项目3，I.Agarwal)。

Proteomics and Lipidomics Core (C. Vary, Core Director) The Proteomics and Lipidomics Core is led by Calvin Vary PhD and provides high quality research design support, sample preparation, mass spectrometry analysis, data collection, and data analysis for a variety of tissues and cells. As a component of the COBRE in Mesenchymal and Neural Regulation of Metabolic Networks since 2017, our services have focused on protein and lipid profiling in mouse and human tissues. Our goals remain to: 1) provide new approaches that expand previous protein identification capabilities, 2) provide unbiased analytic workflows for proteomics and lipidomics studies that include 3) further developing targeted protein (e.g., MRMHR, SRM) and lipid quantitation (MSMSALL, MPIS) workflows, and 4) provide improved statistical and informatics approaches for data interpretation and identification of mechanisms. In Phase I of this COBRE, the Proteomics and Lipidomics Core consistently supported basic, translational, and clinical research projects and grant applications. These have included young investigator-initiated COBRE projects, COBRE pilot projects, and other NIH research applications, both within and outside of MaineHealth Institute for Research. A significant Phase I accomplishment was the award of an NIH S10 shared instrument grant in support of a new high resolution TripleToF mass spectrometer, liquid chromatograph, and other support equipment. MaineHealth provided institutional funds to renovate the facility, which consolidated the current and new equipment in a more efficient footprint. This support has increased our capacity, efficiency, and flexibility by allowing expanded proteomics and lipidomics workflows and increased user access, while providing new opportunities to support ongoing research and training for internal and external users. In phase I, we recruited an outstanding mass spectrometry technology manager, Carlos Gartner PhD, who brought expertise that includes mass spectrometry instrumentation and advanced liquid chromatography. We also recruited Yulica Santos-Ortega, PhD as a research associate with mass spectrometry-based cardiovascular proteomics experience. New Phase II opportunities include exploitation of human proteome-wide selected reaction monitoring protocols using on-line data repositories that will be implemented on new instrumentation (Sciex QTRAP 6500+). We continue to be uniquely positioned as the only regional facility of its kind providing these services for scientific inquiry and in support of student, investigator, and staff training. Within this COBRE, these resources will be critical for promoting junior investigator advancement. This core will advance our understanding of the properties of thermogenic adipocyte lineages and roles in energy balance (Project 1, M. Lynes), provide insight into the role of the X/A cell secretome on bariatric surgery-related bone loss (Project 2, Z. Li). This core will also be well positioned to support PI progress and future exploratory directions for identification of modifiable risk factors in cardiometabolic disease (Project 3, I. Agarwal).